11 December 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Lenalidomide (Revlimid)
  
• Ceritinib (Zykadia)
  
• Beclomethasone dipropionate with eformoterol fumarate dihydrate and glycopyrronium bromide (Trimbow)
  
• Alectinib hydrochloride (Alecensa)
  
• Naloxone hydrochloride (Nalscue)
  
• Nonacog beta pegol (Refixia)
  

Read TC agenda [French]